ClinicalTrials.gg
RecruitingNCT06682988Updated May 26, 2026

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

A Phase 2 interventional study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancers, sponsored by AbbVie. Recruiting at 52 sites in 8 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing mirvetuximab soravtansine in Fallopian Tube Neoplasms — 4 open to participants now, 6 under way, 1 of them phase 3. mirvetuximab soravtansine · Fallopian Tube Neoplasms.

Planned enrollment
8th of 14
110 · median 118
Started
2025
with 2 others
Phase 2
5 of 14
3 open now
Registered
12th of 14
by date
Lead sponsor
6 of 14
AbbVie

Among the 14 studies testing mirvetuximab soravtansine in Fallopian Tube Neoplasms, this one is the 8th largest by planned enrollment, is one of 3 that started in 2025, is one of 5 in phase 2, and was the 12th registered.

Fallopian Tube Neoplasms

835 studies on the registry are indexed under Fallopian Tube Neoplasms; 131 are open to participants now.

Browse Fallopian Tube Neoplasms studies →

Open to participants now

4 of the 14 studies testing mirvetuximab soravtansine in Fallopian Tube Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About mirvetuximab soravtansine

mirvetuximab soravtansine: first FDA approval 2022 (ELAHERE), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 106 Fallopian Tube Neoplasms studies recruiting now, 88 (83%) set no upper age limit and 10 (9%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing mirvetuximab soravtansine in Fallopian Tube Neoplasms, or all of them as a file.
02

Study summary

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of for Mirvetuximab Soravtansine in participants with platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer (platinum-resistant ovarian cancer) (PROC) whose tumors express a high level of folate receptor alpha (FRα).

Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to cancer cells carrying a protein called folate receptor alpha (FRα). There are 2 cohorts in this study, the Randomized Phase 2 Cohort and the Hepatic Impairment Cohort. In the Randomized Phase 2 Cohort, participants are placed in 1 of 2 groups, called treatment arms. Each treatment arm receives MIRV on a different schedule (on day 1 every 21 days or on days 1 and 15 every 28 days). The Hepatic Impairment Cohort is designed to determine the starting dose of MIRV in patients with moderately abnormal liver function. Around 110 participants will be enrolled in the study at approximately 75 sites worldwide.

The total study duration will be approximately 24 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

03

Conditions studied

  • Advanced High-Grade Epithelial Ovarian Cancer
  • Primary Peritoneal Cancer
  • Fallopian Tube Cancers

Keywords

  • Advanced High-Grade Epithelial Ovarian
  • Primary Peritoneal
  • Fallopian Tube Cancers
  • High Folate Receptor-Alpha Expression
  • Platinum Resistant
  • Mirvetuximab Soravtansine
  • MIRV
  • IMGN853
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Both Cohorts

  • Participants with a confirmed diagnosis of high-grade serous epithelial ovarian cancer (EOC), primary peritoneal cancer, or fallopian tube cancer.
  • Participants with platinum-resistant disease:

    • Participants with 1 prior line of platinum-based therapy who have received ≥ 4 cycles of platinum and had a response (complete response (CR) or partial response (PR)) followed by radiological progressive disease (PD) between > 3 months and ≤ 6 months after the date of the last dose of platinum.
    • Participants with 2 or 3 prior lines of platinum-based therapy who had radiological PD ≤ 6 months after the date of the last dose of platinum.
  • Participants with progression diagnosed radiographically on or after their most recent .
  • Participants with an Performance Status (ECOG PS) of 0 or 1.
  • Participants with ≥ 1 lesion that meets the definition of by v1.1 (radiologically measured by the investigator).
  • Participants with a tumor that is positive for folate receptor alpha (FRα) expression as determined by the Ventana folate receptor 1 (FOLR1) assay (≥ 75% of tumor staining at 2+ intensity).

Exclusion criteria

Exclusion Criteria:

Both Cohorts

  • Participants with endometrioid, clear cell, mucinous, or sarcomatous histology; mixed tumors containing any of the above histologies; or low-grade or borderline ovarian tumor.
  • Participants with primary platinum- disease, defined as disease that did not respond (complete response (CR) or partial response (PR)) or that progressed radiographically within 3 months of the last dose of platinum-containing chemotherapy.
  • Participants with serious concurrent illness or active infection as outlined in the protocol
  • Participants with a history of hemorrhagic or ischemic stroke within 6 months prior to randomization.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Randomized Phase 2 Cohort: Arm A

    Participants will receive Mirvetuximab Soravtansine at the standard dose on Day 1 of a 21-day cycle.

    Drug: Mirvetuximab Soravtansine

  • Experimental
    Randomized Phase 2 Cohort: Arm B

    Participants will receive Mirvetuximab Soravtansine at a lower dose than the standard dose on Day 1 and Day 15 of a 28-day cycle .

    Drug: Mirvetuximab Soravtansine

  • Experimental
    Hepatic Impairment Cohort : Mirvetuximab Soravtansine

    Participants will receive Mirvetuximab Soravtansine on Day 1 of a 21-day cycle. Different doses will be given to groups of patients to identify a safe and effective dose.

    Drug: Mirvetuximab Soravtansine

Interventions

06

What researchers measure

Primary outcomes

  1. Randomized Phase 2 Cohort: Percentage of Participants with Grade >= 2 Treatment-Emergent Corneal Adverse Events (AEs)

    An AE is any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of a clinical study, whether or not considered study drug related.

    Time frame: Up to Approximately 24 months

  2. Randomized Phase 2 Cohort: Percentage of Participants who Achieved Objective response rate (ORR)

    ORR is defined as best response of confirmed complete response (CR) or partial response (PR), as assessed by the Investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).

    Time frame: Up to Approximately 24 months

  3. Hepatic Impairment Cohort: Maximal Concentration (Cmax) of Mirvetuximab Soravtansine

    Cmax of MIRV

    Time frame: Up to Approximately 24 months

  4. Hepatic Impairment Cohort: Area Under the Plasma Concentration (AUC) of Mirvetuximab Soravtansine

    AUC of MIRV

    Time frame: Up to Approximately 24 months

  5. Hepatic Impairment Cohort: Trough Concentration (Ctrough) of Mirvetuximab Soravtansine

    Ctrough of MIRV

    Time frame: Up to Approximately 24 months

  6. Hepatic Impairment Cohort: Volume of Distribution at Steady State (Vss) of Mirvetuximab Soravtansine

    Vss) of MIRV

    Time frame: Up to Approximately 24 months

  7. Hepatic Impairment Cohort: Time to Maximal Concentration (Tmax) of Mirvetuximab Soravtansine

    Tmax of MIRV

    Time frame: Up to Approximately 24 months

  8. Hepatic Impairment Cohort: Terminal Half-Life (t1/2) of Mirvetuximab Soravtansine

    t1/2 of MIRV

    Time frame: Up to Approximately 24 months

Secondary outcomes

  1. Randomized Phase 2 Cohort: Percentage of Participants with Treatment-Emergent All-Grade Ocular AEs, Grade >= 2 Peripheral Neuropathy, All-Grade Infusion Reactions, and All-Grade Pneumonitis

    An AE is any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of a clinical study, whether or not considered study drug related.

    Time frame: Up to Approximately 24 months

  2. Randomized Phase 2 Cohort: Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1

    Defined as the time from initial investigator-assessed response (complete response (CR) or partial response (PR)) until progressive disease (PD) as assessed by the investigator or death, whichever occurs first.

    Time frame: Up to Approximately 24 months

  3. Randomized Phase 2 Cohort: Progression-Free Survival (PFS)

    PFS is defined as the time from date of randomization until disease progression or death whichever occurs first.

    Time frame: Up to Approximately 24 months

  4. Randomized Phase 2 Cohort: Overall Survival (OS)

    Overall survival is defined as the time from the date of first dose until the date of death from any cause.

    Time frame: Up to Approximately 24 months

  5. Randomized Phase 2 Cohort: Percentage of Participants With CA-125 Confirmed Clinical Response Per Gynecologic Cancer Intergroup (GCIG) Criteria

    The GCIG CA-125 response is defined as at least 50% reduction in CA-125 levels from baseline. The response must be confirmed and maintained for at least 28 days.

    Time frame: Up to Approximately 24 months

  6. Randomized Phase 2 Cohort: Maximal Concentration (Cmax) of Mirvetuximab Soravtansine

    Cmax of MIRV

    Time frame: Up to Approximately 24 months

  7. Randomized Phase 2 Cohort: Area Under the Plasma Concentration (AUC) of Mirvetuximab Soravtansine

    (AUC) of MIRV

    Time frame: Up to Approximately 24 months

  8. Randomized Phase 2 Cohort: Trough Concentration (Ctrough) of Mirvetuximab Soravtansine

    Ctrough of MIRV

    Time frame: Up to Approximately 24 months

  9. Randomized Phase 2 Cohort: Volume of Distribution at Steady State (Vss) of Mirvetuximab Soravtansine

    Vss of MIRV

    Time frame: Up to Approximately 24 months

  10. Randomized Phase 2 Cohort: Time to Maximal Observed Concentration (Tmax) of Mirvetuximab Soravtansine

    Tmax of MIRV

    Time frame: Up to Approximately 24 months

  11. Randomized Phase 2 Cohort: Terminal Half-Life (t1/2) of Mirvetuximab Soravtansine

    t1/2 of MIRV

    Time frame: Up to Approximately 24 months

  12. Both Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An AE is any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of a clinical study, whether or not considered study drug related.

    Time frame: Up to Approximately 24 months

  13. Both Cohorts: Percentage of Participants with Clinically Significant Vital Sign Measurements as Assessed by the Investigator

    Vital signs include blood pressure, heart rate, respiratory rate, and body temperature.

    Time frame: Up to Approximately 24 months

  14. Both Cohorts: Percentage of Participants with Clinically Significant Laboratory Values (test) as Assessed by the Investigator

    Percentage of participants with clinically significant laboratory values (hematology, chemistry, and coagulation) as assessed by the investigator.

    Time frame: Up to Approximately 24 months

  15. Both Cohorts: Number of Participants With Clinically Significant Abnormalities in Physical Examination Findings

    Physical examination included assessments of general appearance, skin, head (eyes, ears, nose, and throat), neck, lungs, heart, abdomen, back, lymph nodes, extremities, and neurological system.

    Time frame: Up to Approximately 24 months

07

Study locations

52 of 52 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jul 2026, 14 months after the start.

Of 125 phase 2 interventional studies under Fallopian Tube Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2024
First posted
Nov 12, 2024
StartActual
May 28, 2025
Primary completionEst.
Jul 2026
CompletionEst.
Apr 2028
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06682988
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 12, 2024
Start date
May 28, 2025
Primary completion
Jul 2026 (estimated)
Completion
Apr 2028 (estimated)
Last update
May 26, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirvetuximab soravtansine

Start the discussion